Exabis Library
Welcome to the e-CCO Library!
P511: Evaluation of home faecal calprotectin testing to aid remote management and enhanced self-management of Inflammatory Bowel Disease.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P511: Radiological outcomes in perianal fistulising Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P511: Utilisation and efficacy of oral iron therapy in patients with iron deficiency anaemia in a nationwide cohort of ulcerative colitis patients
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P512 Efficacy of tofacitinib for the treatment of moderate-to-severe ulcerative colitis: real-world data
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P512: Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P512: Real world use of adalimumab: effects on corticosteroid treatment and hospital resource utilisation in UK patients with moderate/severe ulcerative colitis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P512: Results of interim analysis of a retrospective IGIBD study on adalimumab use in real practice in Italy: the REAL-life clinical effectiveness of ADAlimumab in ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P512: Safety of reduced clinical monitoring in patients with stable Inflammatory Bowel Disease on maintenance thiopurine therapy
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P512: The counts of white blood cells are not predictive for long-term remission under treatment with thiopurines: a three year Japanese multi-center retrospective cohort study.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P512: Vedolizumab is effective in the prevention and treatment of postoperative recurrence in patients with Crohn´s disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P513: Assessment of quality indicators in The Swedish Inflammatory Bowel Disease Registry (SWIBREG) for Crohn’s Disease treated with biological therapies
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P513: Early initiation of anti-TNF is associated with favourable long-term outcome in Crohn’s disease: Ten-year follow-up data from the Swiss IBD cohort study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P513: Managing IBD patients on adalimumab based on trough levels and antibodies
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P513: Performance of a rapid test for adalimumab monitoring vs. conventional ELISA in a routine laboratory setting
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P513: Prospective study on patients' satisfaction and impact on quality of life of corticosteroid therapy in patients with Inflammatory Bowel Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P513: Treatment persistence in bio-naive patients with long-standing Crohn's disease treated with first-line biologics: real-life data from a Croatian tertiary center.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P514 Does faecal diversion induce clinical response for Crohn’s disease of the colorectum?
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P514: Combination treatment with vedolizumab and anti-TNF-α in inflammatory bowel disease: safety data
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P514: Factors affecting clinical and endoscopic outcomes of placebo arm in trials of biologics and small-molecule drugs in ulcerative colitis: A meta-analysis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM